BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 24495999)

  • 21. Evaluation of a Dual ALK/ROS1 Fluorescent In Situ Hybridization Test in Non-Small-cell Lung Cancer.
    Ginestet F; Lambros L; Le Flahec G; Marcorelles P; Uguen A
    Clin Lung Cancer; 2018 Sep; 19(5):e647-e653. PubMed ID: 29801706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytology specimens offer an effective alternative to formalin-fixed tissue as demonstrated by novel automated detection for ALK break-apart FISH testing and immunohistochemistry in lung adenocarcinoma.
    Rosenblum F; Hutchinson LM; Garver J; Woda B; Cosar E; Kurian EM
    Cancer Cytopathol; 2014 Nov; 122(11):810-21. PubMed ID: 25099128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sensitive and specific detection of EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) specimens by multiplex amplicon RNA massive parallel sequencing.
    Moskalev EA; Frohnauer J; Merkelbach-Bruse S; Schildhaus HU; Dimmler A; Schubert T; Boltze C; König H; Fuchs F; Sirbu H; Rieker RJ; Agaimy A; Hartmann A; Haller F
    Lung Cancer; 2014 Jun; 84(3):215-21. PubMed ID: 24674157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.
    Fang DD; Zhang B; Gu Q; Lira M; Xu Q; Sun H; Qian M; Sheng W; Ozeck M; Wang Z; Zhang C; Chen X; Chen KX; Li J; Chen SH; Christensen J; Mao M; Chan CC
    J Thorac Oncol; 2014 Mar; 9(3):285-94. PubMed ID: 24496003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of
    Reguart N; Teixidó C; Giménez-Capitán A; Paré L; Galván P; Viteri S; Rodríguez S; Peg V; Aldeguer E; Viñolas N; Remon J; Karachaliou N; Conde E; Lopez-Rios F; Nadal E; Merkelbach-Bruse S; Büttner R; Rosell R; Molina-Vila MA; Prat A
    Clin Chem; 2017 Mar; 63(3):751-760. PubMed ID: 28073897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of stained cytologic direct smears for ALK gene rearrangement analysis of lung adenocarcinoma.
    Betz BL; Dixon CA; Weigelin HC; Knoepp SM; Roh MH
    Cancer Cytopathol; 2013 Sep; 121(9):489-99. PubMed ID: 23536384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer.
    Rogers TM; Russell PA; Wright G; Wainer Z; Pang JM; Henricksen LA; Singh S; Stanislaw S; Grille J; Roberts E; Solomon B; Fox SB
    J Thorac Oncol; 2015 Apr; 10(4):611-8. PubMed ID: 25789833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of ALK rearrangements in malignant pleural effusion cell blocks from patients with advanced non-small cell lung cancer: a comparison of Ventana immunohistochemistry and fluorescence in situ hybridization.
    Wang W; Tang Y; Li J; Jiang L; Jiang Y; Su X
    Cancer Cytopathol; 2015 Feb; 123(2):117-22. PubMed ID: 25529354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel mass spectrometry-based assay for diagnosis of EML4-ALK-positive non-small cell lung cancer.
    Sakai K; Okamoto I; Takezawa K; Hirashima T; Kaneda H; Takeda M; Matsumoto K; Kimura H; Fujita Y; Nakagawa K; Arao T; Nishio K
    J Thorac Oncol; 2012 May; 7(5):913-8. PubMed ID: 22722791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan.
    Wu YC; Chang IC; Wang CL; Chen TD; Chen YT; Liu HP; Chu Y; Chiu YT; Wu TH; Chou LH; Chen YR; Huang SF
    PLoS One; 2013; 8(8):e70839. PubMed ID: 23951022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with Crizotinib.
    Hembrough T; Liao WL; Hartley CP; Ma PC; Velcheti V; Lanigan C; Thyparambil S; An E; Monga M; Krizman D; Burrows J; Tafe LJ
    Clin Chem; 2016 Jan; 62(1):252-61. PubMed ID: 26585927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC).
    Shen Q; Wang X; Yu B; Shi S; Liu B; Wang Y; Xia Q; Rao Q; Zhou X
    Lung Cancer; 2015 Dec; 90(3):492-8. PubMed ID: 26477969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer.
    Tan CL; Lim TH; Lim TKh; Tan DS; Chua YW; Ang MK; Pang B; Lim CT; Takano A; Lim AS; Leong MC; Lim WT
    Oncotarget; 2016 Apr; 7(17):23251-62. PubMed ID: 26993609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
    Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R
    Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of ALK rearrangements in 4002 Russian patients: The utility of different diagnostic approaches.
    Demidova I; Grinevich V; Avdalian A; Imyanitov E; Gikalo M; Savelov N; Novikova I; Samuilenkova O; Tiurin V; Ulianova E; Tsimafeyeu I; Tjulandin S
    Lung Cancer; 2017 Jan; 103():17-23. PubMed ID: 28024691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing.
    V Laffert M; Warth A; Penzel R; Schirmacher P; Jonigk D; Kreipe H; Schildhaus HU; Merkelbach-Bruse S; Büttner R; Reu S; Kerler R; Jung A; Kirchner T; Wölfel C; Petersen I; Rodriguez R; Jochum W; Bartsch H; Fisseler-Eckhoff A; Berg E; Lenze D; Dietel M; Hummel M
    Lung Cancer; 2013 Aug; 81(2):200-6. PubMed ID: 23669200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer.
    Lira ME; Kim TM; Huang D; Deng S; Koh Y; Jang B; Go H; Lee SH; Chung DH; Kim WH; Schoenmakers EF; Choi YL; Park K; Ahn JS; Sun JM; Ahn MJ; Kim DW; Mao M
    J Mol Diagn; 2013 Jan; 15(1):51-61. PubMed ID: 23246132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer.
    Pailler E; Adam J; Barthélémy A; Oulhen M; Auger N; Valent A; Borget I; Planchard D; Taylor M; André F; Soria JC; Vielh P; Besse B; Farace F
    J Clin Oncol; 2013 Jun; 31(18):2273-81. PubMed ID: 23669222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.
    Takeuchi K; Choi YL; Soda M; Inamura K; Togashi Y; Hatano S; Enomoto M; Takada S; Yamashita Y; Satoh Y; Okumura S; Nakagawa K; Ishikawa Y; Mano H
    Clin Cancer Res; 2008 Oct; 14(20):6618-24. PubMed ID: 18927303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment.
    Li W; Zhang J; Guo L; Chuai S; Shan L; Ying J
    J Thorac Oncol; 2017 Jan; 12(1):94-101. PubMed ID: 27614248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.